Life Sciences
hVIVO plc
Cavendish exceeded expectations, attracting top-tier investors at a slim discount and generating oversubscribed demand. We’re delighted with the outcome, I’m confident in hVIVO’s growth trajectory as we execute our strategy.” (February 2024)
Cathal Friel
Chairman, hVIVO
Following a successful sell down of £8m in February, on the back of further institutional demand, in July 2024 we sold a further £6m of stock from the founder and Chairman, Cathal Friel. During the course of 2024 we have significantly broadened the register of hVIVO, and a number of high quality UK institutions.
Related News
Leveraging the UK’s Healthcare & Life Science Sector
August 19, 2024
AI Strategy and Guidance
July 24, 2024
Update to the QCA Code
July 2, 2024
Shareholder Activism and Engagement
July 2, 2024
Sector Update – Technology
June 29, 2024
Meet the New Chair of the AIC
June 27, 2024